Lars Fruergaard News Today

Options. Good morning, everyone, and welcome to bloomberg surveillance. I am Francine Lacqua here in london. Now, there is quite a lot going on in the markets, simply because the stimulus in the u. S. Is getting people quite excited. Part of it is what we are hearing from Central Banks around the world, the projections. This is what the markets are doing overall. Stocks are turning higher. Gold at the same time is ascent, and then we have the word on the latest american stimulus package. We need...

Executive later. Another busy day. A lot of people were talking about in the virtual newsroom that we have created around the world that we cant quite remember whether it is tuesday, wednesday, or thursday. A lot of the focus is on what your markets are doing. This is your data, euro area, april services pmi coming up at 12. The preliminary figure was a touch below that. That Services Data coming in at 12 instead of the preliminary 11. 7. That is a little bit better than expected. I am looking f...

Soon. In the fast lane, aston martin plans a fiveyear trade and investment drive in china worth over 600 Million Pounds. We will speak to the ceo, next. We are less than a halfhour from the start of european trading. Take a look at futures right now. We are seeing gains across the board on the major indexes with the exception of the ibex sorry, the ftse mib and stockholm. Here on the board, ftse futures gaining 0. 4 , dax futures up 0. 5 . Lets start with some of the earnings this morning. Roche...

Shells profit slides but the oil maker out maintains its outlook. Confidence signal [inaudible] we are talking to the ceo, the first here on bloomberg. And the fed. Sitting tight. Taking a waitandsee approach as it awaits clarity from the white house. Avp [inaudible] we are less than half an hour from the European Equity market. We will focus on all of the news as we work our way through. Weis start off with the screen. It is pointing to a negative stock. London looks like it will outperform a l...

Novo Nordisk's India plans, Atul Satija's faith in social enterprises, PhonePe's arrival in Sri Lanka are some of the stories that piqued the interest of our readers this week

Novo Nordisk, maker of the blockbuster drugs for diabetes and weight loss respectively, has a market capitalisation of $592.02 billion, making it larger than the entire Danish economy. The company's global CEO talks about its India plans and the need for competition to ramp up innovation in pharma

We could soon be looking at a revolutionary new path to weight loss: a pill that is administered orally. The drug by pharmaceutical company Novo Nordisk is..

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, announces that the company is facing demand outstripping supply, a problem it plans to gradually improve over the next year. The ramp-up in production...

Novo Nordisk A/S misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were $0.77.

Lilly’s newest obesity and diabetes medicines, widely known as GLP-1 drugs, are drawing rave reviews from doctors, researchers and patients for their ability to safely and effectively control blood sugar and take off weight.